Posttraumatic stress disorder, sleep and medical cannabis treatment: A daily diary study Sharon R. Sznitman, David Meiri, Ben H. Amit, Dennis Rosenberg, Talya Greene Journal of Anxiety Disorders, 2022, 92, 102632 Doi : 10.1016/j.janxdis.2022.102632 Abstract Despite increasing use of Medical Cannabis (MC) among posttraumatic stress disorder(PTSD) patients, research is lacking on how MC treatment relates to PTSD symptomatology, in particular sleep disturbances. This study examines the time gap between MC use and sleep onset and its association with (1) number of awakenings throughout the night, (2) early awakenings, (3) nightmares. Each morning over a two week period, 77 licensed MC patients suffering from PTSD reported [...]
Lire la suiteAssessment of clinical outcomes in patients with post-traumatic stress disorder: analysis from the UK Medical Cannabis Registry Manaswini Pillai, Simon Erridge, Lara Bapir, Martha Nicholas, Nishaanth Dalavaye, Carl Holvey, Ross Coomber, Daniela Barros, Urmila Bhoskar, Gracia Mwimba, Kavita Praveen, Chris Symeon, Simmi Sachdeva-Mohan, James J Rucker and Mikael H Sodergren Expert Review of Neurotherapeutics, 2022, 22, 11–12, 1009–1018. Doi : 10.1080/14737175.2022.2155139 ABSTRACT Background : The current paucity of clinical evidence limits the use of cannabis-based medicinal products (CBMPs) in post-traumatic stress disorder (PTSD). This study investigates health-related quality of life (HRQoL) changes and adverse events in patients prescribed CBMPs for PTSD. Methods : A case-series of patients [...]
Lire la suiteIncreased cannabis intake during the COVID-19 pandemic is associated with worsening of depression symptoms in people with PTSD A. Murkar, T. Kendzerska, J. Shlik, L. Quilty, M. Saad and R. Robillard BMC Psychiatry, 2022, 22, 554 Doi : 10.1186/s12888-022-04185-7 Abstract Background: Some evidence suggests substance use affects clinical outcomes in people with posttraumatic stress disorder (PTSD). However, more work is required to examine links between mental health and cannabis use in PTSD during exposure to external stressors such as the COVID-19 pandemic. This study assessed mental health factors in individuals with self-reported PTSD to: (a) determine whether stress, anxiety, and depression symptoms were associ- ated with changes [...]
Lire la suiteMort du chercheur Raphael Mechoulam, chantre du chanvre médical par Charles Delouche-Bertolasi Libération,13 mars 2023 Pionnier de l’utilisation médicale du cannabis, le scientifique israélien est mort le 9 mars à Jérusalem, à l’âge de 92 ans. Entre autres découvertes, il est celui qui a réussi en 1964 à isoler le THC, principe actif du cannabis. Raphael Mechoulam, lors d'une conférence à Tel Aviv, en mars 2016. (JACK GUEZ/AFP) Depuis quelques jours, certains fumeurs de joints dédient leurs exhalaisons à un homme, qui vient de s’éteindre en Israël à l’âge de 92 ans : le docteur Raphael Mechoulam, chimiste et scientifique, chercheur pionnier à l’origine de la découverte du delta-9 [...]
Lire la suitePharmacologie du Cannabidiol : Points de vigilance, conséquences et risques chez l’homme Note rédigée par l’Association Française des centres d’Addictovigilance : Pr Joëlle MICALLEF, Dr Anne BATISSE, Dr Bruno REVOL, décembre 2021 Thérapies, 2022, 77, (5), 585-590. Doi : 10.1016/j.therap.2022.02.001 Contexte Le Cannabidiol (CBD) est l’un des principaux phytocannabinoïdes présent dans Cannabis sativa, avec le THC. A ce jour, un seul produit contenant uniquement du CBD (nom de ce médicament Epidyolex®) est disponible sur le marché français, son Autorisation de Mise sur le Marché (AMM) lui conférant une indication médicale en association au clobazam dans le traitement des crises d’épilepsie associées au syndrome de Lennox-Gastaut ou au [...]
Lire la suiteCBD FOR PAIN : WHAT DOES THE SCIENCE SAY ? A new book by three distinguished scientists reviews the current status of CBD as a treatment for acute and chronic illness. By Linda A. Parker, Erin M. Rock, and Raphael Mechoulam on October 04, 2022 Excerpted from CBD: What Does the Science Say ? by Linda A. Parker, Erin M. Rock, and Raphael Mechoulam, published by MIT Press (2022, 309 pp.). A large proportion of medicinal cannabis patients are using cannabis to treat pain syndromes, particularly for chronic pain alleviation. Cannabis use for unmanageable pain has been shown to reduce the dose of opiates [...]
Lire la suiteCannabinoids and Endocannabinoids, and Prospective Modulation of EC Signaling in Neurodegenerative, Cardiovascular and Allied Disorders Dr Vinod Nikhra Preprint, May 2019 Doi : 10.13140/RG.2.2.36649.24165 ABSTRACT CANNABIS USE AND AVAILABILITY: The Cannabis derivatives have been used for recreational and medicinal purposes since ancient times. Because of the additive potential of cannabis products, their sale, possession and use are variously regulated in different countries throughout the world. Still as a psychoactive drug, cannabis continues to find extensive favour among recreational and medical users in the USA and other countries having led to decriminalise cannabis use for recreational and medicinal purposes. ECS: RECEPTORS, LIGANDS AND SIGNALING: The endocannabinoid system comprises [...]
Lire la suiteMECHOULAM ON THE FUTURE OF CANNABINOID RESEARCH The father of cannabis science emphasized three key areas to pursue By Martin A. Lee on March 15, 2023 I was fortunate to cross paths with Raphael Mechoulam, “the father of cannabis research,” at several science conferences over the years. The most memorable occasion was the 22nd annual meeting of the International Cannabinoid Research Society (ICRS) in Freiburg, Germany, in July 2012. Mechoulam delivered a plenary speech at the symposium, addressing the future of cannabinoid research and key areas of study that should be pursued. It was exactly fifty years earlier, in 1962, when Mechoulam launched his [...]
Lire la suiteCannabidiol as an add-on therapy to overcome the slow-onset and, possibly, resistance to antidepressant treatment : involvement of NAPE-PLD in the medial prefrontal cortex. Franciele F. Scarante, Vinícius D. Lopes, Eduardo J. Fusse, Maria A. Vicente, Melissa R. Araújo, Davi S. Scomparin, Rafael P. Aguiar, Francisco S. Guimarães, Viviani Nardinid, Carlos Arterio Sorgid, Lucia H. Faccioli, RhD, PhDd, Jaime E. C. Hallak, MD, PhDe,f; Samia Joca, Kenneth Mackie, Antonio Waldo Zuardi, José Alexandre S. Crippa, Alline C. Campos. bioRxiv preprint, April 26, 2021. doi : 10.1101/2021.04.23.441143 Highlights ● In mice, cannabidiol (CBD), but not escitalopram, induced a fast-onset anti-stress action. ● Combinations of sub-effective doses [...]
Lire la suiteAre cannabidiol and Δ9-tetrahydrocannabivarin negative modulators of the endocannabinoid system? A systematic review John M McPartland, Marnie Duncan, Vincenzo Di Marzo and Roger G Pertwee British Journal of Pharmacology, 2015, 172, 737-753. Doi : 10.1111/bph.12944 Based upon evidence that the therapeutic properties of Cannabis preparations are not solely dependent upon the presence of Δ9-tetrahydrocannabinol (THC), pharmacological studies have been recently carried out with other plant cannabinoids (phytocannabinoids), particularly cannabidiol (CBD) and Δ9-tetrahydrocannabivarin (THCV). Results from some of these studies have fostered the view that CBD and THCV modulate the effects of THC via direct blockade of cannabinoid CB1 receptors, thus behaving like first-generation CB1 [...]
Lire la suite